摘要:
The present invention discloses pharmaceutical-grade ferric organic compounds having enhanced dissolution rate. These ferric organic compounds, including but are not limited to ferric citrate, are useful for treating chronic kidney disease.
摘要:
The present invention is directed to forms of ferric organic compounds, uses thereof, and methods of making same. The present invention discloses a novel physical form of ferric citrate with dissolution properties desirable for use in medicine, including the treatment of hyperphosphatemia and metabolic acidosis.
摘要:
The present invention is directed to forms of ferric organic compounds, uses thereof, and methods of making same. The present invention discloses a novel physical form of ferric citrate with dissolution properties desirable for use in medicine, including the treatment of hyperphosphatemia and metabolic acidosis.
摘要:
The present invention discloses pharmaceutical-grade ferric organic compounds having enhanced dissolution rate. These ferric organic compounds, including but are not limited to ferric citrate, are useful for treating chronic kidney disease.
摘要:
The present invention is directed to forms of ferric organic compounds, uses thereof, and methods of making same. The present invention discloses a novel physical form of ferric citrate with dissolution properties desirable for use in medicine, including the treatment of hyperphosphatemia and metabolic acidosis.
摘要:
The present invention discloses pharmaceutical-grade ferric organic compounds having enhanced dissolution rate. These ferric organic compounds, including but are not limited to ferric citrate, are useful for treating chronic kidney disease.
摘要:
The present invention discloses apharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels.
摘要:
A two-layer controlled-release oral preparation, which comprises a first ingredient as a quick-release layer and a second ingredient as a controlled-release layer, wherein the first ingredient comprises a xanthine derivative, and the second ingredient comprises a xanthine derivative and an enteric excipient. No more than 35% by weight of the xanthine derivative in the second ingredient is released within 90 min after in vitro elution, and 50% or more by weight of the xanthine derivative in the second ingredient is released within 3 h after in vitro elution.
摘要:
The present invention discloses pharmaceutical-grade ferric organic compounds having enhanced dissolution rate. These ferric organic compounds, including but are not limited to ferric citrate, are useful for treating chronic kidney disease.